Tenascin-C: Exploitation and collateral damage in cancer management

59Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Despite an increasing knowledge about the causes of cancer, this disease is difficult to cure and still causes far too high a death rate. Based on advances in our understanding of disease pathogenesis, novel treatment concepts, including targeting the tumor microenvironment, have been developed and are being combined with established treatment regimens such as surgical removal and radiotherapy. Yet it is obvious that we need additional strategies to prevent tumor relapse and metastasis. Given its exceptional high expression in most cancers with low abundance in normal tissues, tenascin-C appears an ideal candidate for tumor treatment. Here, we will summarize the current applications of targeting tenascin-C as a treatment for different tumors, and highlight the potential of this therapeutic approach.

Cite

CITATION STYLE

APA

Spenlé, C., Saupe, F., Midwood, K., Burckel, H., Noel, G., & Orend, G. (2015). Tenascin-C: Exploitation and collateral damage in cancer management. Cell Adhesion and Migration. Taylor and Francis Inc. https://doi.org/10.1080/19336918.2014.1000074

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free